Clinical Trial Update: Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05) [Phase 2]

View source ↗

Summary

Phase 2 randomized trial evaluating neoadjuvant radiotherapy plus tegafur, oxaliplatin, iparomlimab, and tuvonralimab in resectable gastric and gastroesophageal…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• OXALIPLATIN (Oxaliplatin)
• Tuvonralimab (tuvonralimab)
• iparomlimab
• tegafur (tegafur)

Snippet

Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Conditions: Immunotherapy, Gastric Cancer (GC) | Phase 2 | Status: RECRUITING